These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 32260160

  • 1. Nobiletin Promotes Megakaryocytic Differentiation through the MAPK/ERK-Dependent EGR1 Expression and Exerts Anti-Leukemic Effects in Human Chronic Myeloid Leukemia (CML) K562 Cells.
    Yen JH, Lin CY, Chuang CH, Chin HK, Wu MJ, Chen PY.
    Cells; 2020 Apr 03; 9(4):. PubMed ID: 32260160
    [Abstract] [Full Text] [Related]

  • 2. Silencing of membrane-associated sialidase Neu3 diminishes apoptosis resistance and triggers megakaryocytic differentiation of chronic myeloid leukemic cells K562 through the increase of ganglioside GM3.
    Tringali C, Lupo B, Cirillo F, Papini N, Anastasia L, Lamorte G, Colombi P, Bresciani R, Monti E, Tettamanti G, Venerando B.
    Cell Death Differ; 2009 Jan 03; 16(1):164-74. PubMed ID: 18820643
    [Abstract] [Full Text] [Related]

  • 3. Regulation of the Erk2-Elk1 signaling pathway and megakaryocytic differentiation of Bcr-Abl(+) K562 leukemic cells by Gab2.
    Dorsey JF, Cunnick JM, Mane SM, Wu J.
    Blood; 2002 Feb 15; 99(4):1388-97. PubMed ID: 11830491
    [Abstract] [Full Text] [Related]

  • 4. [Growth inhibition and differentiation of imatinib-resistant chronic myeloid leukemia cell induced by cell differentiation agent in vitro].
    Wang XD, Qiu L, Lu RZ, Chen LJ, Zhan ZM, Han BH, Zhang BL, Ma J.
    Zhonghua Yi Xue Za Zhi; 2007 Dec 25; 87(48):3399-405. PubMed ID: 18476538
    [Abstract] [Full Text] [Related]

  • 5. CD69 partially inhibits apoptosis and erythroid differentiation via CD24, and their knockdown increase imatinib sensitivity in BCR-ABL-positive cells.
    Huang SY, Liu YH, Chen YJ, Yeh YY, Huang HM.
    J Cell Physiol; 2018 Sep 25; 233(9):7467-7479. PubMed ID: 29663362
    [Abstract] [Full Text] [Related]

  • 6. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
    Zhang GS, Liu DS, Dai CW, Li RJ.
    Am J Hematol; 2006 Apr 25; 81(4):242-55. PubMed ID: 16550520
    [Abstract] [Full Text] [Related]

  • 7. Spred2 modulates the erythroid differentiation induced by imatinib in chronic myeloid leukemia cells.
    Yang Y, Liu X, Xiao F, Xue S, Xu Q, Yin Y, Sun H, Xu J, Wang H, Zhang Q, Wang H, Wang L.
    PLoS One; 2015 Apr 25; 10(2):e0117573. PubMed ID: 25688862
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. 5-Demethylnobiletin Inhibits Cell Proliferation, Downregulates ID1 Expression, Modulates the NF-κB/TNF-α Pathway and Exerts Antileukemic Effects in AML Cells.
    Chen PY, Wang CY, Tsao EC, Chen YT, Wu MJ, Ho CT, Yen JH.
    Int J Mol Sci; 2022 Jul 02; 23(13):. PubMed ID: 35806401
    [Abstract] [Full Text] [Related]

  • 10. Revealing genome-wide mRNA and microRNA expression patterns in leukemic cells highlighted "hsa-miR-2278" as a tumor suppressor for regain of chemotherapeutic imatinib response due to targeting STAT5A.
    Kaymaz BT, Günel NS, Ceyhan M, Çetintaş VB, Özel B, Yandım MK, Kıpçak S, Aktan Ç, Gökbulut AA, Baran Y, Can BK.
    Tumour Biol; 2015 Sep 02; 36(10):7915-27. PubMed ID: 25953263
    [Abstract] [Full Text] [Related]

  • 11. miR-101 sensitizes K562 cell line to imatinib through Jak2 downregulation and inhibition of NF-κB target genes.
    Farhadi E, Zaker F, Safa M, Rezvani MR.
    Tumour Biol; 2016 Oct 02; 37(10):14117-14128. PubMed ID: 27517565
    [Abstract] [Full Text] [Related]

  • 12. ZNF300 knockdown inhibits forced megakaryocytic differentiation by phorbol and erythrocytic differentiation by arabinofuranosyl cytidine in K562 cells.
    Cai J, Gong R, Yan F, Yu C, Liu L, Wang W, Lin Y, Guo M, Li W, Huang Z.
    PLoS One; 2014 Oct 02; 9(12):e114768. PubMed ID: 25485965
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
    Xin P, Li C, Zheng Y, Peng Q, Xiao H, Huang Y, Zhu X.
    Drug Des Devel Ther; 2017 Oct 02; 11():1115-1126. PubMed ID: 28435223
    [Abstract] [Full Text] [Related]

  • 14. Divalproex sodium enhances the anti-leukemic effects of imatinib in chronic myeloid leukemia cells partly through SIRT1.
    Wang W, Zhang J, Li Y, Yang X, He Y, Li T, Ren F, Zhang J, Lin R.
    Cancer Lett; 2015 Jan 28; 356(2 Pt B):791-9. PubMed ID: 25449787
    [Abstract] [Full Text] [Related]

  • 15. A natural-like synthetic small molecule impairs bcr-abl signaling cascades and induces megakaryocyte differentiation in erythroleukemia cells.
    Turroni S, Tolomeo M, Mamone G, Picariello G, Giacomini E, Brigidi P, Roberti M, Grimaudo S, Pipitone RM, Di Cristina A, Recanatini M.
    PLoS One; 2013 Jan 28; 8(2):e57650. PubMed ID: 23460890
    [Abstract] [Full Text] [Related]

  • 16. Induction of megakaryocytic differentiation in chronic myelogenous leukemia cell K562 by 3-hydrogenkwadaphnin.
    Meshkini A, Yazdanparast R.
    J Biochem Mol Biol; 2007 Nov 30; 40(6):944-51. PubMed ID: 18047790
    [Abstract] [Full Text] [Related]

  • 17. Overexpression of Hes1 is involved in sensitization of K562 cells to Imatinib.
    Eskandari S, Yazdanparast R.
    J Cell Biochem; 2019 Jun 30; 120(6):10128-10136. PubMed ID: 30548309
    [Abstract] [Full Text] [Related]

  • 18. Idelalisib induces G1 arrest and apoptosis in chronic myeloid leukemia K562 cells.
    Chen Y, Zhou Q, Zhang L, Wang R, Jin M, Qiu Y, Kong D.
    Oncol Rep; 2016 Dec 30; 36(6):3643-3650. PubMed ID: 27748929
    [Abstract] [Full Text] [Related]

  • 19. Activin A induction of erythroid differentiation sensitizes K562 chronic myeloid leukemia cells to a subtoxic concentration of imatinib.
    Huang YW, Lee WH, Tsai YH, Huang HM.
    Am J Physiol Cell Physiol; 2014 Jan 01; 306(1):C37-44. PubMed ID: 24088895
    [Abstract] [Full Text] [Related]

  • 20. Gene therapy for BCR-ABL+ human CML with dual phosphorylation resistant p27Kip1 and stable RNA interference using an EBV vector.
    Sengupta A, Banerjee D, Chandra S, Banerjee S.
    J Gene Med; 2006 Oct 01; 8(10):1251-61. PubMed ID: 16952195
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.